Conflict of interest: J.-M.H. received fees for advisory boards or lectures from Alexion, Astra Zeneca, Bayer, Boehringer Ingelheim France, Novo Nordisk, Servier, and Vifor Fresenius Pharma. L.F. received consulting fees from AstraZeneca, Bayer, Bristol Myers Squibb–Pfizer, Boehringer Ingelheim, and Novo Nordisk; and lecture fees from AstraZeneca, Bristol Myers Squibb–Pfizer, Boehringer Ingelheim, Boston Scientific, Medtronic, Novo Nordisk, and Zoll Medical. A.K. received consultancy fees from GSK, Vifor, Novartis, and Otsuka; received honoraria from Pfizer, Astra-Zeneca, GSK, Novartis, Vifor, Otsuka, and Bohringer-Ingelheim; has an advisory or leadership role for Novartis, Vifor, and Otsuka; and Speakers Bureau for Otsuka, Vifor, Pfizer, Astra-Zeneca, and Boehringer-Ingelheim. C.A. received honoraria from Lilly, Sanofi, Novo Nordisk, Decom. D.E. received travel grant and honoraria from Alnylam and participated to the advisory board of Alnylam and Novo Nordisk. P.R. reports receiving personal fees from AstraZeneca, Bayer, Boehringer Ingelheim, Fresenius, Idorsia, Novo Nordisk, and Vifor. G.C. received honoraria for advisory board and participating symposia by Astellas Pharma, GSK, CSL, Vifor, and Novo Nordisk. P.Z. received honoraria and consulting fees from Novo Nordisk, Astra-Zeneca, Boehringer Lilly, and Bayer. N.G. received honoraria from AstraZeneca, Bayer, Boehringer, Lilly, Novartis, Novo Nordisk. S.H. received institutional research grants from Astra-Zeneca, Asten Santé, Air Liquide Health Science, Bayer, Boehringer Ingelheim, Eli Lilly, Homeperf, ISIS Diabète, LVL, Nestle Home Care, Novo Nordisk, Pierre Fabre, Sanofi, Valbiotis and Vitalaire and served as consultant and/or received honoraria from Astra-Zeneca, Bayer, Boehringer Ingelheim, Eli Lilly, Mundi-pharma, Novo Nordisk, Novartis, Sanofi, Servier and Valbiotis.
PubMed
